Jacqueline Nicholas

1.1k total citations
47 papers, 507 citations indexed

About

Jacqueline Nicholas is a scholar working on Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health and Neurology. According to data from OpenAlex, Jacqueline Nicholas has authored 47 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pathology and Forensic Medicine, 12 papers in Public Health, Environmental and Occupational Health and 9 papers in Neurology. Recurrent topics in Jacqueline Nicholas's work include Multiple Sclerosis Research Studies (36 papers), Acute Lymphoblastic Leukemia research (12 papers) and Polyomavirus and related diseases (6 papers). Jacqueline Nicholas is often cited by papers focused on Multiple Sclerosis Research Studies (36 papers), Acute Lymphoblastic Leukemia research (12 papers) and Polyomavirus and related diseases (6 papers). Jacqueline Nicholas collaborates with scholars based in United States, Germany and Switzerland. Jacqueline Nicholas's co-authors include Aaron Boster, Daniel Ontaneda, Wei‐Shi Yeh, Ming‐Yi Huang, Andrew Lee, Michael K. Racke, Michael Edwards, Roger Edwards, Anna Dellarole and Amy Phillips and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jacqueline Nicholas

44 papers receiving 500 citations

Peers

Jacqueline Nicholas
Carrie M. Hersh United States
Johannes Lorscheider Switzerland
José Manuel García‐Domínguez Spain
Aurora Zanghì Italy
Hanna Kuusisto Finland
Emmanuelle Leray France
Sonalee Agarwal United States
Francisco Gascón Spain
Olivier Heinzlef France
A Calò Italy
Carrie M. Hersh United States
Jacqueline Nicholas
Citations per year, relative to Jacqueline Nicholas Jacqueline Nicholas (= 1×) peers Carrie M. Hersh

Countries citing papers authored by Jacqueline Nicholas

Since Specialization
Citations

This map shows the geographic impact of Jacqueline Nicholas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline Nicholas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline Nicholas more than expected).

Fields of papers citing papers by Jacqueline Nicholas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline Nicholas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline Nicholas. The network helps show where Jacqueline Nicholas may publish in the future.

Co-authorship network of co-authors of Jacqueline Nicholas

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline Nicholas. A scholar is included among the top collaborators of Jacqueline Nicholas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline Nicholas. Jacqueline Nicholas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ross, Amy Perrin, Jacqueline Nicholas, Stephen T. Yeung, et al.. (2025). Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis. BMC Neurology. 25(1). 28–28.
2.
3.
Sotirchos, Elias S., Matthew D. Smith, Anna DuVal, et al.. (2023). Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis. Neurology. 101(23). e2448–e2453. 6 indexed citations
4.
5.
Schirda, Brittney, et al.. (2022). Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis. Multiple Sclerosis and Related Disorders. 59. 103651–103651. 6 indexed citations
6.
Cohen, Jeffrey A., Robert A Bermel, Carrie M. Hersh, et al.. (2022). Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Multiple Sclerosis Journal. 28(7). 1131–1137. 15 indexed citations
7.
Nicholas, Jacqueline, et al.. (2022). Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab. Multiple Sclerosis and Related Disorders. 63. 103921–103921. 6 indexed citations
8.
Hauser, Stephen L., Anne H. Cross, Kevin Winthrop, et al.. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple Sclerosis Journal. 28(10). 1576–1590. 45 indexed citations
9.
Fountain‐Zaragoza, Stephanie, et al.. (2021). Employing Connectome-Based Models to Predict Working Memory in Multiple Sclerosis. Brain Connectivity. 12(6). 502–514. 11 indexed citations
10.
Nicholas, Jacqueline, et al.. (2019). PND91 PREDICTORS OF NON-ADHERENCE AMONG PATIENTS WITH MULTIPLE SCLEROSIS NEWLY INITIATING ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS. Value in Health. 22. S287–S287. 1 indexed citations
11.
12.
Wray, Sibyl, François Jacques, Tamara Miller, et al.. (2019). Treatment Sequencing and Satisfaction With Alemtuzumab in Relapsing Multiple Sclerosis Patients: Interim Results of the Real-world PRO-ACT Study (P3.2-097). Neurology. 92(15_supplement). 1 indexed citations
13.
Nicholas, Jacqueline, et al.. (2019). Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data. BMC Neurology. 19(1). 258–258. 28 indexed citations
14.
Ontaneda, Daniel, Jacqueline Nicholas, Jia Zhou, et al.. (2018). Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US. Multiple Sclerosis and Related Disorders. 27. 101–111. 42 indexed citations
15.
Nicholas, Jacqueline, Daniel Ontaneda, Ning Wu, et al.. (2017). Development of an Algorithm to Identify Multiple Sclerosis (MS) Disease Severity Based on Healthcare Costs in a US Administrative Claims Database (P2.052). Neurology. 88(16_supplement). 10 indexed citations
16.
Boster, Aaron, Jacqueline Nicholas, Ning Wu, et al.. (2017). Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database. Neurology and Therapy. 6(1). 91–102. 63 indexed citations
17.
Nicholas, Jacqueline, Aaron Boster, Ning Wu, et al.. (2017). COMPARATIVE EFFECTIVENESS OF DELAYED-RELEASE DIMETHYL FUMARATE VERSUS FINGOLIMOD AND TERIFLUNOMIDE ON RISK OF RELAPSE (P6.375). Neurology. 88(16_supplement). 2 indexed citations
18.
Derfuß, Tobias, Daniel Ontaneda, Jacqueline Nicholas, Xiangyi Meng, & Kathleen Hawker. (2016). Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. Multiple Sclerosis and Related Disorders. 8. 124–130. 32 indexed citations
19.
Deleidi, Michela, David Pitt, Kedar Mahajan, et al.. (2015). Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation-Induced Neurodegeneration. Stem Cells Translational Medicine. 4(3). 252–260. 17 indexed citations
20.
Racke, Michael K., et al.. (2014). Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate. Drug Design Development and Therapy. 8. 897–897. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carrie M. Hersh Breakdown of academic impact, for papers by Johannes Lorscheider Breakdown of academic impact, for papers by José Manuel García‐Domínguez Breakdown of academic impact, for papers by Aurora Zanghì Breakdown of academic impact, for papers by Hanna Kuusisto Breakdown of academic impact, for papers by Emmanuelle Leray Breakdown of academic impact, for papers by Sonalee Agarwal Breakdown of academic impact, for papers by Francisco Gascón Breakdown of academic impact, for papers by Olivier Heinzlef Breakdown of academic impact, for papers by A Calò
Rankless by CCL
2026